ER-positive breast cancer
Clinical trials for ER-positive breast cancer explained in plain language.
Never miss a new study
Get alerted when new ER-positive breast cancer trials appear
Sign up with your email to follow new studies for ER-positive breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for advanced breast cancer: drug combo trial opens
Disease control OngoingThis early-phase study tests a new drug called OP-1250 (palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find safe doses and check for side effects. About 190 adults will joi…
Matched conditions: ER-POSITIVE BREAST CANCER
Phase 1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for advanced breast cancer: OP-1250 faces off against standard care
Disease control OngoingThis study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…
Matched conditions: ER-POSITIVE BREAST CANCER
Phase 3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug targets rare cancer mutation in early trial
Disease control OngoingThis early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…
Matched conditions: ER-POSITIVE BREAST CANCER
Phase 1 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New study explores letrozole's effects on breast cancer before surgery
Disease control OngoingThis study tests the drug letrozole in postmenopausal women with early-stage ER+ breast cancer. Participants take letrozole for 4 to 24 weeks before surgery to see how the tumor changes and to check if they take the medication as prescribed. The goal is to improve treatment for t…
Matched conditions: ER-POSITIVE BREAST CANCER
Phase 2 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Promising breast cancer drug trial pulled before starting
Disease control CancelledThis study aimed to see if the drug trastuzumab deruxtecan worked better than standard CDK4/6 inhibitors for people with a specific advanced breast cancer (ER-positive, HER2-low, non-luminal A). It was designed for adults with metastatic disease. However, the trial was withdrawn …
Matched conditions: ER-POSITIVE BREAST CANCER
Phase 3 • Sponsor: Danish Breast Cancer Cooperative Group • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug combo aims to stop breast cancer from coming back
Disease control OngoingThis Phase 2 trial is testing whether adding the drug ribociclib (Kisqali) to standard hormone therapy can improve outcomes for people with early-stage ER-positive breast cancer. The study involves 120 participants and focuses on clearing cancer DNA from the blood. The goal is to…
Matched conditions: ER-POSITIVE BREAST CANCER
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug combo shows promise in shrinking breast tumors before surgery
Disease control OngoingThis study tests a combination of two drugs, lenvatinib and letrozole, given before surgery to postmenopausal women with a common type of breast cancer (hormone receptor positive). The goal is to see if the drugs can shrink the tumor enough to improve surgical outcomes. About 40 …
Matched conditions: ER-POSITIVE BREAST CANCER
Phase 1/2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Blood test may help doctors switch cancer treatment earlier
Knowledge-focused OngoingThis study looks at whether a blood test that tracks tumor DNA (ctDNA) can help doctors switch treatments earlier in people with metastatic breast cancer. The goal is to see if acting on a molecular signal of progression, before symptoms or scans show it, can keep the cancer unde…
Matched conditions: ER-POSITIVE BREAST CANCER
Phase 2 • Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC